Patents | DVAX Message Board Posts

Dynavax Technologies Corporation

  DVAX website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

DVAX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1333 of 1708  at  10/29/2018 8:22:42 AM  by

warlord_2010


 In response to msg 1331 by  peterahoward
view thread

Re: Patents

This was published one week after Heplisav was approved: 

Asked during the conference call about an ongoing intellectual property dispute regarding Heplisav-B, Michael Ostrach, chief business officer, said he does not "expect the patents controlled by GSK and Merck will prevent us from marketing Heplisav-B, and although we don't discuss details of ongoing discussions, I think it's fair to say that all three companies would agree that the best outcome for all of us will be license agreements containing reasonable royalty terms or the equivalent. You'll recall that the GSK-controlled patents expire in June or about a quarter after our launch."

 

Kenilworth, N.J.-based Merck & Co. Inc.'s patent "expires about two and a half years after launch, [but] Merck's out of the market, based on their announcement, for all of next year," he said. Merck has said worldwide demand caused a shortage of its Recombivax-HB.
 
http://www.bioworld.com/content/savoring-acip-victory-dynavax-looks-ahead-heplisav-b-price-come-0


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 6     Views: 246
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1334 Re: Patents fairvalueforyou 5 10/29/2018 8:40:40 AM
1335 Re: Patents peterahoward 2 10/29/2018 1:11:18 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...